Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.45 -0.2%	$8.89	$7.35 ▼ $13.70	$2.55B	0.11	458,067 shs	469,269 shs
CRNX Crinetics Pharmaceuticals	$30.92 +5.2%	$30.02	$24.10 ▼ $62.53	$2.91B	0.33	1.00 million shs	1.36 million shs
GHRS GH Research	$13.08 +0.7%	$13.87	$6.00 ▼ $20.50	$680.53M	0.98	267,506 shs	93,162 shs
XENE Xenon Pharmaceuticals	$38.84 +1.7%	$33.16	$26.74 ▼ $46.00	$2.99B	1.16	1.06 million shs	1.19 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.24%	+5.36%	-7.75%	-17.80%	-31.85%
CRNX Crinetics Pharmaceuticals	+5.17%	+0.65%	-0.19%	+3.90%	-42.70%
GHRS GH Research	+0.69%	+2.27%	-8.15%	+17.10%	+17.94%
XENE Xenon Pharmaceuticals	+1.73%	+1.60%	+24.53%	+30.55%	-0.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	2.3622 of 5 stars	3.3	4.0	0.0	2.5	0.0	0.6
CRNX Crinetics Pharmaceuticals	3.6702 of 5 stars	3.4	0.0	3.7	3.4	2.5	0.0
GHRS GH Research	2.6854 of 5 stars	3.4	3.0	0.0	2.7	2.5	0.0
XENE Xenon Pharmaceuticals	2.0522 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.50	Moderate Buy	$14.00	65.68% Upside
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$68.86	122.69% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	144.65% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	36.97% Upside

Current Analyst Ratings Breakdown

Latest GHRS, XENE, ALVO, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/11/2025	CRNX Crinetics Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$90.00 ➝ $86.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.18	N/A	N/A	($0.57) per share	-14.82
CRNX Crinetics Pharmaceuticals	$1.04M	2,800.04	N/A	N/A	$12.44 per share	2.49
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
XENE Xenon Pharmaceuticals	$9.43M	317.60	N/A	N/A	$8.22 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.23	36.74	42.25	N/A	11.26%	-38.36%	9.28%	N/A
CRNX Crinetics Pharmaceuticals	-$298.41M	-$4.11	N/A	N/A	N/A	N/A	-32.28%	-29.45%	11/11/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	11/11/2025 (Estimated)

Latest GHRS, XENE, ALVO, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ALVO Alvotech	-$0.26	$0.14	+$0.40	$0.14	$120.51 million	$116.02 million
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.82	1.27
CRNX Crinetics Pharmaceuticals	N/A	17.80	17.80
GHRS GH Research	N/A	29.49	29.49
XENE Xenon Pharmaceuticals	N/A	15.14	15.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CRNX Crinetics Pharmaceuticals	98.51%
GHRS GH Research	56.90%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
CRNX Crinetics Pharmaceuticals	4.60%
GHRS GH Research	41.60%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	94.18 million	89.84 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.97 million	Optionable

GHRS, XENE, ALVO, and CRNX Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLC

August 23 at 7:48 AM | marketbeat.com

Candriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

August 23 at 7:07 AM | marketbeat.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

August 23 at 4:04 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLC

August 22 at 4:43 AM | marketbeat.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued

August 21 at 8:14 AM | finance.yahoo.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

August 21 at 4:18 AM | marketbeat.com

Lord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 19, 2025 | marketbeat.com

What is Chardan Capital's Forecast for XENE FY2025 Earnings?

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for XENE Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for XENE

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst

August 16, 2025 | marketbeat.com

William Blair Has Negative Estimate for XENE Q3 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

August 16, 2025 | americanbankingnews.com

Leerink Partnrs Issues Positive Outlook for XENE Earnings

August 16, 2025 | americanbankingnews.com

William Blair Has Pessimistic Outlook of XENE Q3 Earnings

August 16, 2025 | americanbankingnews.com

What is William Blair's Estimate for XENE FY2027 Earnings?

August 15, 2025 | marketbeat.com

Xenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Chardan Capital

August 14, 2025 | marketbeat.com

Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

August 14, 2025 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade

August 13, 2025 | marketbeat.com

Royal Bank Of Canada Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, XENE, ALVO, and CRNX Company Descriptions

Alvotech NASDAQ:ALVO

$8.45 -0.02 (-0.24%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.71 +0.26 (+3.08%)

As of 08/22/2025 07:42 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.92 +1.52 (+5.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$30.95 +0.03 (+0.11%)

As of 08/22/2025 07:58 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

GH Research NASDAQ:GHRS

$13.08 +0.09 (+0.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.10 +0.02 (+0.15%)

As of 08/22/2025 06:21 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Xenon Pharmaceuticals NASDAQ:XENE

$38.84 +0.66 (+1.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.84 0.00 (0.00%)

As of 08/22/2025 07:32 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time